[go: up one dir, main page]

DK0398327T4 - Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil - Google Patents

Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil

Info

Publication number
DK0398327T4
DK0398327T4 DK90109337.7T DK90109337T DK0398327T4 DK 0398327 T4 DK0398327 T4 DK 0398327T4 DK 90109337 T DK90109337 T DK 90109337T DK 0398327 T4 DK0398327 T4 DK 0398327T4
Authority
DK
Denmark
Prior art keywords
binding protein
tnf
necrosis factor
tumor necrosis
antibodies
Prior art date
Application number
DK90109337.7T
Other languages
English (en)
Other versions
DK0398327T3 (da
Inventor
Hartmut Engelmann
Daniela Novick
David Wallach
Dan Aderka
Menachem Rubinstein
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27271388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0398327(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL9033989A external-priority patent/IL90339A/en
Priority claimed from IL9122989A external-priority patent/IL91229A/en
Priority claimed from IL94039A external-priority patent/IL94039A/en
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0398327T3 publication Critical patent/DK0398327T3/da
Publication of DK0398327T4 publication Critical patent/DK0398327T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK90109337.7T 1989-05-18 1990-05-17 Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil DK0398327T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL9033989A IL90339A (en) 1989-05-18 1989-05-18 Anti-cytotoxic protein and its purification
IL9122989A IL91229A (en) 1989-08-06 1989-08-06 Antibodies to tbp-i and pharmaceutical compositions containing them
IL94039A IL94039A (en) 1989-08-06 1990-04-06 Antibodies to tbp - 1 and their use

Publications (2)

Publication Number Publication Date
DK0398327T3 DK0398327T3 (da) 1995-05-22
DK0398327T4 true DK0398327T4 (da) 2013-04-15

Family

ID=27271388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90109337.7T DK0398327T4 (da) 1989-05-18 1990-05-17 Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil

Country Status (9)

Country Link
US (1) US8138323B2 (da)
EP (1) EP0398327B2 (da)
JP (1) JP2866706B2 (da)
AT (1) ATE119942T1 (da)
AU (1) AU636608B2 (da)
CA (2) CA2017025C (da)
DE (1) DE69017753T3 (da)
DK (1) DK0398327T4 (da)
ES (1) ES2072330T5 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
IL107267A (en) * 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1994009137A1 (en) * 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
AU709054B2 (en) 1994-03-07 1999-08-19 Chiron Corporation Compositions for the inhibition of TNF formation and uses thereof
US5486595A (en) * 1994-04-01 1996-01-23 Centecor, Inc. Tumor necrosis factor inhibitors
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
IL139574A0 (en) * 1998-05-18 2002-02-10 Applied Research Systems TNF-RII (p75) AGONISTS FOR TREATING ASTHMA AND OTHER ALLERGIC CONDITIONS
DE19948867A1 (de) * 1998-10-09 2000-08-17 Bioserv Ag TNFalpha bindende Peptide und ihre Anwendung für Detektion, Inaktivierung und/oder Entfernung von TNFalpha aus biologischen Flüssigkeiten
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
RU2007119989A (ru) * 2004-12-02 2009-01-10 Домантис Лимитед (Gb) Композиции, слитые конструкции и конъюгаты plad домена
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2015153144A1 (en) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
EP3136098B1 (en) * 2014-04-23 2020-12-09 Konica Minolta, Inc. Medium for resin particles containing fluorescent dye
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CA3052095A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
IL319561A (en) 2017-02-07 2025-05-01 Janssen Biotech Inc Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine

Also Published As

Publication number Publication date
ATE119942T1 (de) 1995-04-15
JPH03197499A (ja) 1991-08-28
ES2072330T3 (es) 1995-07-16
US20030124675A1 (en) 2003-07-03
EP0398327B2 (en) 2013-02-20
EP0398327A1 (en) 1990-11-22
AU636608B2 (en) 1993-05-06
CA2017025A1 (en) 1990-11-18
DE69017753T2 (de) 1995-07-13
ES2072330T5 (es) 2013-06-24
AU5514190A (en) 1990-11-22
CA2458875A1 (en) 1990-11-18
EP0398327B1 (en) 1995-03-15
DE69017753T3 (de) 2013-06-20
US8138323B2 (en) 2012-03-20
DE69017753D1 (de) 1995-04-20
DK0398327T3 (da) 1995-05-22
JP2866706B2 (ja) 1999-03-08
CA2017025C (en) 2008-07-22

Similar Documents

Publication Publication Date Title
DK0398327T4 (da) Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil
DE3852255D1 (de) Tumor-Nekrosisfaktor-Inhibitor-Protein und dessen Reinigung.
JO1425B1 (en) New vehicles
NO852673L (no) Tumor-nekrosefaktor.
DK162222C (da) 2-amino-5-hydroxy-4-methylpyrimidin-derivater og farmeceutiske praeparater indeholdende disse
FI914409A0 (fi) Kalciumupptagande inhibitorer.
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
FI863971A7 (fi) Farmaseuttinen koostumus käytettäväksi leukopenian hoidossa.
FI894459A0 (fi) Menetelmä uusien kinolyylioksatsol-2-onien valmistamiseksi, jotka ovat käyttökelpoisia proteiinikinaasi C:n inhibiittoreina
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
DK164055C (da) 2-thioxo-5-pyrimidincarboxamider, farmaceutisk middel indeholdende disse til at inducere regression af leukaemi og haemning af vaekst af tumorer og fremgangsmaader til deres fremstilling
SE8901342L (sv) Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi
NO913683D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
IT1177147B (it) Composizione farmaceutica per combattere infezioni virali, e procedimento di uso per le infezioni virali
FI914410A0 (fi) Kalciumupptagande inhibitorer.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
FR2558061B1 (fr) Composition pour solutions de rehydratation par voie orale des nourrissons et solutions la contenant
IT8847937A0 (it) Composizione per il trattamento dimateriali cinematografici
DE3770133D1 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.